Skip to main content
. 2022 Dec 23;13(1):37. doi: 10.3390/diagnostics13010037

Table 1.

Clinical Studies on IBD Remote Monitoring and Management.

Platform Study Design Outcomes
Telemonitoring of Crohn’s disease and Ulcerative colitis (TECCU) [13] RCT, n = 63
  • -

    Report symptoms

  • -

    Receive education and reminders
  • -

    Improvement in disease activity and remission status

  • -

    Fewer phone calls and outpatient visits
Home telemanagement system for Ulcerative Colitis (UC HAT) [14] RCT, n = 24
  • -

    Patients surveyed about disease activity, therapy adherence, side effects

  • -

    Measure weight weekly

  • -

    Educational curriculum
  • -

    No improvement in disease activity, quality of life, or adherence
HealthPromise [15,16] RCT, n = 320
  • -

    Patients update quality report cards biweekly, track symptoms and quality of life

  • -

    Providers receive reminders and alerts
  • -

    Improved quality of life
MyIBDcoach [17] RCT, n = 909
  • -

    Patients report disease activity, treatment adherence, side effects, smoking, quality of life, depression and anxiety symptoms

  • -

    Nutritional assessment
  • -

    No difference in mean number of flares, corticosteroid courses, emergency room visits, surgeries

  • -

    Improved treatment adherence, fewer outpatient visits and phone calls, fewer hospitalizations, lower IBD-related care costs
eIBD [18] Prospective study
UC, n = 194
CD, n = 217
  • -

    Patients surveyed on disease activity, quality of life, exercise, nutrition

  • -

    Responses trigger alerts to providers
  • -

    Fewer endoscopies, decreased healthcare utilization, decreased long-term steroid use
TELE-IBD [19] RCT, n = 348
  • -

    Surveyed on symptoms, HBI or SCCAI, medication side effects, quality of life

  • -

    Patients categorized into green, yellow, or red zones of disease activity

  • -

    Providers are altered and individualized plans created for each participant

  • -

    Educational curriculum
  • -

    Decrease in hospitalizations

  • -

    Increase in non-invasive diagnostic tests, phone calls, electronic encounters

  • -

    No differences in disease activity or quality of life
Constant Care [20,21] Prospective study
Mesalamine, n = 94
Infliximab, n = 27
  • -

    Tracking of disease activity, fecal calprotectin, HBI, or SCCAI

  • -

    Patients categorized into green, yellow, or red zones of disease activity

  • -

    Protocolized treatment response for mesalamine or infliximab dosing based on zone of disease activity

 Mesalamine dosing:
  • -

    Significant improvement in quality of life

Infliximab dosing:
  • -

    No difference in hospitalizations, surgical interventions, use of corticosteroids

  • -

    Reduced number of infusions and associated reduction in cost